A division of Glanbia plc, an international nutritional solutions and cheese group headquartered in Ireland, Glanbia Nutritionals manufactures and sells nutritional and functional ingredient solutions to the food, beverage, supplement, and animal nutrition industries.
"MenaQ7 PURE is the newest offering to Glanbia Nutritionals' arsenal of unique, proprietary, branded, clinically substantiated, and validated ingredients," said Hogne Vik, CEO of NattoPharma. "The market for vitamin K2 as MK-7 is clearly expanding as the scientific evidence of its ability to promote bone and cardiovascular health continues to accumulate. As vitamin K2 awareness has been rapidly growing, NattoPharma has been fielding an influx of inquiries. Glanbia Nutritionals' broad and deep customer base will benefit from this vital new offering, which will further enhance NattoPharma’s U.S. presence.”
“This is a breakthrough for the work we have been consistently advancing in the United States, as we have said that we have been in contact with some large U.S. companies. Building strong partnerships is a long process, but one that is extremely gratifying when it comes to fruition,” continued Froce Marc Bohan, Chairman of the Board at NattoPharma. "Glanbia's expertise and network is a fantastic start to help create a healthier, more robust population."
NattoPharma's MenaQ7 PURE is produced in a European pharmaceutical manufacturing facility and is fully validated by numerous human clinical studies, as well as in vivo and in vitro research; it is recognized by the world’s leading experts in vitamin K2 at University of Maastricht (Netherlands) for purity and quality.